Cambridge, Mass. – October 18, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted unanimously (10 to 0) that the risk-benefit profile of…Original Article
FDA Advisory Committee Recommends Approval of Shire’s Prucalopride (SHP555) for Chronic Idiopathic Constipation
